Oxaliplatin induced-neuropathy in digestive tumors

被引：58

作者：

Sereno, Maria ^{[1
]}

Gutierrez-Gutierrez, Gerardo ^{[2
]}

Gomez-Raposo, Cesar ^{[1
]}

Lopez-Gomez, Miriam ^{[1
]}

Merino-Salvador, Maria ^{[1
]}

Zambrana Tebar, Francisco ^{[1
]}

Rodriguez-Antona, Cristina ^{[3
]}

Casado, Enrique ^{[1
]}

机构：

[1] Infanta Sofia Univ Hosp, Dept Med Oncol, Madrid 28702, Spain

[2] Infanta Sofia Univ Hosp, Dept Neurol, Neuromuscular Unit, Madrid 28702, Spain

[3] Natl Ctr Oncol Res, Madrid 28015, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2014年 / 89卷 / 01期

关键词：

Oxaliplatin; Peripheral neuropathy; Digestive tumors; INDUCED PERIPHERAL NEUROPATHY; PHASE-II TRIAL; SIMPLIFIED BIMONTHLY LEUCOVORIN; COLORECTAL-CANCER; ADVANCED ADENOCARCINOMA; 5-FLUOROURACIL REGIMEN; 1ST-LINE TREATMENT; 2ND-LINE THERAPY; DOUBLE-BLIND; CHEMOTHERAPY;

D O I：

10.1016/j.critrevonc.2013.08.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oxaliplatin is one of the main drugs used in digestive tumors treatment. Peripheral neuropathy is a well-recognized dose-limiting toxicity of OXL. Two types of neuropathy have been described with this agent: acute or transient and chronic or persistent, with different etiology, clinical manifestations and prognosis. This paper is an exhaustive review about the main aspects of oxaliplatin induced peripheral neuropathy, focus in clinical features, treatment, prevention strategies and future approach. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：166 / 178

页数：13

共 90 条

[1] First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study [J].

Afchain, P. ;

Chibaudel, B. ;

Lledo, G. ;

Selle, F. ;

Bengrine-Lefevre, L. ;

Nguyen, S. ;

Paitel, J. -F. ;

Mineur, L. ;

Artru, P. ;

Andre, T. ;

Louvet, C. .

BULLETIN DU CANCER, 2009, 96 (05) :E18-E22

[2]

Agafitei RD, 2004, J CLIN ONCOL, V22, p270S

[3] Interventions for preventing neuropathy caused by cisplatin and related compounds [J].

Albers, James W. ;

Chaudhry, Vinay ;

Cavaletti, Guido ;

Donehower, Ross C. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02)

[4]

Alejandro LM, 2012, AM J CLIN ONCOL-CANC, V27, P63

[5] Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Colangelo, Linda H. ;

Lopa, Samia H. ;

Petrelli, Nicholas J. ;

Goldberg, Richard M. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390

[6] Technology literature review: Quantitative sensory testing [J].

Chong P.S.T. ;

Cros D.P. .

MUSCLE & NERVE, 2004, 29 (05) :734-747

[7] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[8] Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? [J].

Antonacopoulou, A. G. ;

Argyriou, A. A. ;

Scopa, C. D. ;

Kottorou, A. ;

Kominea, A. ;

Peroukides, S. ;

Kalofonos, H. P. .

EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (07) :963-968

[9] Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy [J].

Argyriou, A. A. ;

Chroni, E. ;

Polychronopoulos, P. ;

Iconomou, G. ;

Koutras, A. ;

Makatsoris, T. ;

Gerolymos, M. K. ;

Gourzis, P. ;

Assimakopoulos, K. ;

Kalofonos, H. P. .

NEUROLOGY, 2006, 67 (12) :2253-2255

[10]

Argyriou AA, 2012, EUR J NEUROL, V17, P25

← 1 2 3 4 5 6 7 8 9 →